REVIEW Vandetanib is an orally available receptor tyrosine kinase (RTK) inhibitor, which blocks both the vascular endothelial growth factor (VEGF) RTK and the Epidermal Growth Factor (EGF) RTK. Blockade of the VEGF receptors limits the growth of new blood vessels, which are vital to supporting the growth of tumors. Without sufficient blood supply, tumor cells become starved for nutrients, slowing or halting growth. Vandetanib is specifically indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. The Journal of clinical endocrinology and metabolism 2010 Jun;95(6):2664-71.
Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Feb 10;28(5):767-72.
Sathornsumetee S, Rich JN Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today 2006 Oct;42(10):657-70.